Education
About Us
Working with TipRanks
Follow Us
Evotec AG (EVO)
NASDAQ:EVO
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.3Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -2.64%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with strong performance in the Just - Evotec Biologics segment and progress in strategic collaborations offset by declines in Shared R&D revenue and overall group revenue. Cost reduction initiatives are on track, but the increased net debt and leverage pose challenges.Company Guidance
During the Evotec SE Q1 2025 earnings call, the company reiterated its guidance for the full fiscal year. Evotec expects group revenues to reach between €840 million and €880 million, with R&D expenditure ranging from €40 million to €50 million. The company also anticipates an adjusted EBITDA of €30 million to €50 million. Despite a 4% year-over-year decline in group revenues to €200 million for Q1 2025, driven by a 9.4% decrease in Shared R&D revenues to €140.6 million, the Just - Evotec Biologics segment showed strong growth, recording €59.4 million in revenue. The company also highlighted progress in cost-saving measures, including a 33% reduction in R&D spending and a reduction in headcount. Moreover, Evotec reconfirmed its mid-term outlook, projecting an average annual growth rate of 8% to 12% over the next four years and an EBITDA margin exceeding 20% by 2028.Strong Performance in Just - Evotec Biologics
The segment reported €59.4 million in revenue, exceeding expectations and showing strong growth compared to Q1 2024.
Progress in Strategic Collaborations with BMS
Significant advancements in collaborations, including a US$20 million payment for progress in neurology and €75 million for achievements in oncology.
Cost Reduction Initiatives on Track
Achieved more than 50% of planned savings through site closures, headcount reduction, and discretionary spend control by the end of Q1 2025.
Grant from Korean Government
Received a grant to develop novel antibody treatments for lung fibrosis, enhancing capabilities in drug discovery and future revenue streams.
---
EVO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EVO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $4.17 | $4.05 | -2.88% |
Apr 17, 2025 | $3.27 | $3.60 | +10.09% |
Nov 06, 2024 | $4.58 | $3.86 | -15.72% |
Aug 14, 2024 | $3.32 | $3.31 | -0.30% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Evotec AG (EVO) report earnings?
Evotec AG (EVO) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Evotec AG (EVO) earnings time?
Evotec AG (EVO) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVO EPS forecast?
EVO EPS forecast for the fiscal quarter 2025 (Q2) is -0.05.
---